Drug & intervention
Phesgo
RxCUI 2382605
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Clinical trials
5 shownThe SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerNCT06439693 · 2024-08-08
RECRUITINGA Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerNCT05894239 · 2023-09-08
RECRUITINGNeoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast CancerNCT05306041 · 2023-01-02
RECRUITINGClassifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-BlockadeNCT06068985 · 2024-09-05
ACTIVE_NOT_RECRUITINGA Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)NCT05296798 · 2022-07-18
ACTIVE_NOT_RECRUITINGConditions being studied
Research locations
Leading sponsors
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.